NCT05158166View on ClinicalTrials.gov

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 2, 2025

Conditions
Adductor Spasmodic DysphoniaVoice DisordersSpasmodic Dysphonia
Interventions
DRUG

DaxibotulinumtoxinA

This is a long-acting alternative to traditional Botox A treatment.

Trial Locations (1)

94118

UCSF, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT05158166 - DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia | Biotech Hunter | Biotech Hunter